Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 10, 2006, Pages 741-748

  Al Khaja, K A Jassim ^a   Sequeira, R P ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Drug utilization (trend); Hypertension; Indapamide; Perindopril; Prescription surgery; WHO ISH guidelines

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRISERIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ESSENTIAL DRUG; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INDAPAMIDE; LISINOPRIL; METHYLDOPA; PERINDOPRIL; PROPRANOLOL; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ARTICLE; BAHRAIN; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC HYPERTENSION; DRUG CHOICE; DRUG SUBSTITUTION; DRUG UTILIZATION; HEALTH CARE FACILITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; WORLD HEALTH ORGANIZATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BAHRAIN; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; COMMUNITY HEALTH CENTERS; DRUG UTILIZATION; DRUGS, ESSENTIAL; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; WORLD HEALTH ORGANIZATION;

EID: 33750491938     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1161     Document Type: Article

References (39)

1. Glynn RJ, Brock DB, Harris T, et al. Use of antihypertensive drugs and trends in blood pressure in the elderly. Arch Intern Med 1995; 155: 1855-1860.
2. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among elderly patients. JAMA 1993; 270: 1837-1841.
3. Manolio TA, Cutter JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995; 155: 829-837.
4. Monane M, Glynn RJ, Gurwitz JH, Bohn RL, Levin R, Avorn J. Trends in medication choices for hypertension in the elderly: the decline of the thiazides. Hypertension 1995; 25: 1045-1051.
5. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing. JAMA 1997; 278: 1745-1748.
6. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arrh Intern Med 1988; 48:1023-1038.
7. Rotmensch HH, Mendelevitch L, Silverberg DS, Liron M. Prescribing pattern of antihypertensive drugs in the community. J Hum Hypertens 1996; 10: S169-S172.
8. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers in the treatment of hypertension. In Hypertension: A Comparison to Brenner and Rector's. The Kidney, Oparil S. Weber MA (eds). Saunders: Philadelphia, 2000; 389-398.
9. Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results: Multiple Risk Factor Intervention Trial (MRFIT) Research Group. JAMA 1982; 248: 1465-1477.
10. Al Khaja KAJ, Sequeira RP, Abdul Wabab AWM, Mathur VS. Antihypertensive drug prescription trends at the primary health care centres in Bahrain. Pharmacoepidemiol Drug Safe 2001; 10: 219-227.
11. World Health Organization/Intenational Society of Hypertension (WHOASH). Guidelines sub-committee: guidelines for management of hypertension. J Hypertens 1999; 17: 151-183.
12. Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
14. The National High Blood Pressure Education Programme Working Group. National High Blood Pressure Education Programme Warldng Group Report on hypertension in diabetes. Hypertension 1994; 23: 145-158.
15. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
16. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood control in diverse North American Settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-405.
17. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97-104.
18. Ramsay LE, Williams B, Johnston GD, for the British Hypertension Society et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
19. Dahlof B, Lindholm LH, Hansson L, Scherseten B, Ekborn T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
20. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24 hour blood pressure mean and variability to severity of target damage in hypertension. Hypertension 1987; 5: 93-98.
21. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24 hour blood pressure variability. J Hypertens 1993; 11: 1133-1137.
22. Ambrosioni E, Safar M, Degante JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustained release indapamide: results of randomized double-blind controlled studies. J Hypertens 1998; 16: 1677-1684.
23. Lacourciere Y, Provencher R Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressure in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27: 371-376.
24. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
25. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
26. Hausson L, Lindholm LH, Niskanen L, for the Captopril Prevention Project (CAPPP) Study Group, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet 1999; 353: 611-616.
27. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 Study. Lancer 1999; 354: 1751-1756.
28. Wing LM, Reid C, Ryan P, for the Second Australian National Blood Pressure Study Group, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
29. Messerli FH, Grossman E, Goldbourt U. Antihypertensive therapy in diabetic hypertensive patients. Am J Hyperten 2001; 14: 12S-16S.
30. Tatti P, Pahor M, Byington RP, et al. Outcomes results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
31. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
32. Lebovitz HE, Wiegmann TB, Cnaan A. et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994; 45: S150-SI55.
33. Lewis EJ, Hunsicker KG, Bain TP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
34. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney 1997; 51: 2-15.
35. Salvetti A, Argenio GF, Borgi G, Bemini GP. Management of hypertension and metabolic disorders. In Metabolic Aspect of Hypertension, Kaplan NM (ed.). Science Press Ltd.: London, 1994; 6.1-6.19.
36. Croog SH, Levine S, Sudilovsky A, Baume RM, Clive J. Sexual symptoms in hypertensive patients: a clinical trial of antihypertensive medications. Arch Intern Med 1988; 148: 788-794.
37. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of angiotensin-converting enzyme, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153.
38. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery (EUROPA) Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients. with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA Study). Lancet 2003; 362: 782-788.
39. Al Mahroos F. McKeigue PM. Ifigh prevalence of diabetes in Bahrainis: association with ethnicity and raised plasma cholesterol. Diabetes Care 1998; 21: 939-942.